You are visiting us from Ohio. You are located in HHS Region 5. Your Center is Great Lakes ATTC.

Addiction Science Made Easy (ASME)

Research Brief Catalog

Addiction Science Made Easy, currently written by Meg Brunner, MLIS (Northwest ATTC and the NIDA CTN Dissemination Library), features two research papers per month, explaining the science in clear language and putting the findings in context for addiction workforce members. One paper typically comes from NIDA’s National Drug Abuse Treatment Clinical Trials Network (CTN), the other from a SAMHSA-funded project.
Cost-Effectiveness and Benefits to Quality of Life of XR-NTX vs BUP-NX for the Treatment of Opioid Use Disorder
Meg Brunner, MLIS
Murphy SM, et al. Economic evaluation of extended-release injectable naltrexone compared to buprenorphine-naloxone initiated in inpatient settings for treatment of opioid use disorder: Results derived from the X:BOT clinical trial. CHERISH factsheet, May 2021. Free online, http://ctndisseminationlibrary.org/PDF/1482.pdf.
Published: January 12, 2021
Would Physicians Find a Clinical Decision Support System Helpful for Identifying/Managing Opioid Use Disorder?
Meg Brunner, MLIS
Solberg LI, et al. Clinician perceptions about a decision support system to identify and manage opioid use disorder. Journal of the American Board of Family Medicine 2021;34:1096-1102. Free online, https://www.jabfm.org/content/34/6/1096.
Published: January 12, 2021
Impact of Medication for Opioid Use Disorder on Symptoms of Depression
Meg Brunner, MLIS
Wang K, et al. Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. Journal of Affective Disorders 2021 (in press). Find it in the CTN Dissemination Library (http://ctndisseminationlibrary.org/dbtw-wpd/exec/dbtwpub.dll?BU=http%3A//ctndisseminationlibrary.org/ctnsearch.htm&QY=find%20AutoNumber%20/%20Status%20ct%20%28%281481%29%26finished%29&TN=ctnlibrary&DF=Full&RF=Full&AC=QBE_QUERY&CS=0&MF=searchbutton.ini&NP=0)
Published: January 11, 2021
Documentation of Medicinal Cannabis Use and Associated Health Conditions in Electronic Health Records in Washington State
Meg Brunner, MLIS
Matson TE, et al. Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State. JAMA Network Open 2021;4(5):e219375. Free online (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103224/)
Published: January 11, 2021
Psychiatric Symptoms in Youth with Opioid Use Disorder Differ by Sex but Improve During Buprenorphine/Naloxone Treatment
Meg Brunner, MLIS
Hammond CJ, et al. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders. Journal of Substance Abuse Treatment 2021 (in press).
Published: January 10, 2021
Predicting Which Patients Might Benefit from Exercise as a Treatment for Stimulant Use Disorder
Meg Brunner, MLIS
Rethorst CD, et al. Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction Using Dosed Exercise (STRIDE) CTN-0037 study. Mental Health and Physical Activity 2021 (in press).
Published: January 10, 2021
Disparities in Digital Access Among Rural/Urban Americans Leaves Many Out of Telemedicine
Meg Brunner, MLIS
Curtis ME, et al. Disparities in digital access among American rural and urban households and implications for telemedicine-based services. Journal of Rural Health 2021 (in press).
Published: January 9, 2021
Screening Patients at Community Pharmacies for Cannabis and Opioid Co-Use May Provide Useful Health Risk Information
Meg Brunner, MLIS
Bryan MA, et al. Concomitant cannabis misuse and associations with depression, pain and substance misuse among patients prescribed opioids. Pharmacy 2021;9:134.
Published: January 9, 2021
Race, Psychosocial Characteristics, and Treatment Outcomes for People with Cannabis Use Disorder
Meg Brunner, MLIS
Ullrich HS, et al. Race, psychosocial characteristics, and treatment outcomes among individuals undergoing treatment for cannabis use disorder: A latent profile analysis based on preferred method of using cannabis. Journal of Substance Abuse Treatment 2021 (in press).
Published: January 8, 2021
Emergency Department-Administered High-Dose Buprenorphine May Improve Outcomes for People with OUD
Meg Brunner, MLIS
Herring AA, et al. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Network Open 2021;4(7):e2117128.
Published: January 8, 2021
Screening for Suicidal Thoughts and Behaviors in Trauma-Exposed People with SUDs
Meg Brunner, MLIS
Skye S, et al. Graded response item response theory in scaling suicidal thoughts and behaviors among trauma-exposed women with substance use disorders. Psychology of Addictive Behaviors 2021 (in press).
Published: January 7, 2021
Smartwatch-Type Sensors Accurately Detect Cocaine Use
Meg Brunner, MLIS
Ertin E, et al. An examination of the feasibility of detecting cocaine use using smartwatches. Frontiers in Psychiatry 2021 (in press).
Published: January 7, 2021
More Therapy Sessions Result in Better Outcomes for Youth in Treatment for Opioid Use Disorder
Meg Brunner, MLIS
Hammond CJ, et al. Therapy dose mediates the relationship between buprenorphine/naloxone and opioid treatment outcomes in youth receiving medication for opioid use disorder treatment. Journal of Addiction Medicine 2021 (in press).
Published: January 6, 2021
Best Approaches for Alcohol and Drug Screening in Primary Care
Meg Brunner, MLIS
McNeely J, et al. Comparison of methods for alcohol and drug screening in primary care clinics. JAMA Network Open 2021;4(5):e2110721.
Published: January 6, 2021
Is Telemedicine the Answer to Rural Expansion of Medication Treatment for OUD?
Meg Brunner, MLIS
Hser Y, et al. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. Addiction Science & Clinical Practice 2021;16:24.
Published: January 5, 2021
Study Participants Who Remained on Medication Treatment for OUD Post-Trial Had Better Outcomes at 36 Weeks
Meg Brunner, MLIS
Greiner MG, et al. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. Journal of Substance Abuse Treatment 2021 (in press)
Published: January 5, 2021
Prevalence and Medication Treatment of Opioid Use Disorder Among Patients with HCV or HIV
Meg Brunner, MLIS
Tsui JI, et al. Prevalence and medication treatment of opioid use disorder among primary care patients with hepatitis C and HIV. Journal of General Internal Medicine 2021 (in press).
Published: January 3, 2021
Combination of Bupropion and Naltrexone for Treatment of Methamphetamine Use Disorder Shows Promise
Meg Brunner, MLIS
Citation: Trivedi MH, et al. Bupropion and naltrexone in methamphetamine use disorder. New England Journal of Medicine 2021;384:140-153
Published: January 3, 2021
Patient Perspectives on Initiating Treatment with Extended-Release Naltrexone (XR-NTX)
Meg Brunner, MLIS
Gauthier P, et al. Patients’ perspectives on initiating treatment with extended-release naltrexone (XR-NTX). Journal of Substance Abuse Treatment 2021 (in press).
Published: April 2, 2021
Physician-Pharmacist Collaborative Care Model Improves Access to Buprenorphine
Meg Brunner, MLIS
Wu L, et al. Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients with Opioid Use Disorder: Results from a Multisite Study of the National Drug Abuse Treatment Clinical Trials Network. Addiction 2021 (in press).
Published: April 2, 2021
Integrating Telemedicine for Medication Treatment for OUD in Rural Primary Care: Beyond the COVID Pandemic
Meg Brunner, MLIS
Hser Y & Mooney LJ. Integrating telemedicine for medication treatment for opioid use disorder in rural primary care: Beyond the COVID pandemic. Journal of Rural Health 2020 (in press).
Published: January 12, 2020
Are Reductions in WHO Drinking Risk Levels a Valid Treatment Target for Alcohol Use Disorders in Teens with ADHD?
Meg Brunner, MLIS
Mitchell HM, et al. Are non-abstinent reductions in World Health Organization drinking risk level a valid treatment target for alcohol use disorders in adolescents with ADHD? Addictive Behaviors Reports 2020 (in press).
Published: January 12, 2020
Opioid Use Disorder in Women and the Implications for Treatment
Meg Brunner, MLIS
Barbosa-Leiker C, et al. Opioid use disorder in women and the implications for treatment. Psychiatric Research and Clinical Practice 2020 (in press).
Published: January 11, 2020
Comparing Web-Based Platforms for Promoting HIV Self-Testing and PrEP Uptake in High-Risk Men
Meg Brunner, MLIS
Lemley SM, et al. Comparing web-based platforms for promoting HIV self-testing and PrEP uptake in high-risk MSM: Protocol for a longitudinal cohort study. JMIR Research Protocols 2020 (in press).
Published: January 11, 2020
1 2 3 4 5 … 36
Copyright © 2024 Addiction Technology Transfer Center (ATTC) Network
map-markermagnifiercrossmenuchevron-down